Abstract: Tacrolimus (TAC) is a first-line immunosuppressant used to prevent organ rejection after kidney transplantation. There is large inter-individual variability in its pharmacokinetics. Single nucleotide polymorphisms (SNPs) in genes encoding TAC metabolizing enzymes cytochromes P450 3A4/5 (CYP3A4/5), P-glycoprotein efflux transporter (ABCB1), their expression regulator pregnane X receptor (NR1I2) and CYP3A co-factor cytochrome P450 reductase (POR) have been studied for their effects on tacrolimus disposition. However, except for CYP3A5*3, controversies remain about their roles in predicting dose-adjusted trough blood TAC concentrations (C 0 /D). This study aimed to investigate the effects of ABCB1 (61A>G, 1199G>A, 1236C>T, 2677G>T and 3435C>T), CYP3A4*22, CYP3A5*3, NR1I2 (8055C>T, 63396C>T and -25385C>T) and POR*28 SNPs on TAC C 0 /D. In total, 165 kidney transplant recipients were included in this study. SNPs were genotyped by probe-based real-time polymerase chain reaction. Associations between log-transformed whole blood TAC C 0 /D (measured at 1 and 3 months post-transplant) and genotypes/haplotypes were assessed by linear mixed effects analysis, controlling for age, sex and haematocrit. It was observed that CYP3A5 expressors (*1/*1 + *1/*3) (p = 5.5 9 10 À16 ) and ABCB1 61G allele carriers (p = 0.001) had lower logtransformed TAC C 0 /D (56% and 26% lower geometric mean TAC C 0 /D, respectively) and accounted for approximately 30% and 4%, respectively, of log-transformed TAC C 0 /D variability in the first 3 months post-transplant. In conclusion, CYP3A5*3 is a major, and ABCB1 61A>G is a novel, although minor, genetic factor affecting TAC C 0 /D in kidney transplant recipients.
End stage renal disease is a substantial health and economic burden worldwide. Compared with dialysis, kidney transplantation remains the most effective treatment for such patients, and post-surgery immunosuppressive therapy has increased the first-year graft survival rate to over 90% [1] . Tacrolimus (TAC) is one of the first-line immunosuppressants widely used to prevent organ rejection after kidney transplantation; however, it has a narrow therapeutic index [2] and large inter-individual dose and trough blood concentration (C 0 ) variability [3] .
Tacrolimus undergoes extensive intestinal and hepatic metabolism whilst renal clearance accounts for less than 1% of total body clearance [4] . Its pharmacokinetics (PK) is mainly determined by its metabolizing enzymes cytochromes P450 (CYP) 3A5 (encoded by CYP3A5) and 3A4 (encoded by CYP3A4) [5, 6] , and the efflux transporter P-glycoprotein (Pgp, encoded by ABCB1) [7] . Cytochrome P450 reductase (encoded by POR) is essential for CYP3A activity [8] and the pregnane X receptor (encoded by NR1I2) regulates CYP3A4/5 and P-gp expression [9] ; with the potential for these genes to affect TAC PK. However, only CYP3A5*3 [the most common CYP3A5 single nucleotide polymorphism (SNP)] significantly affects TAC PK across different studies [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The CYP3A5*3 allele (6986A>G, rs776746) leads to nonfunctional CYP3A5 [21] , and consequently, transplant recipients with CYP3A5*3/*3 genotype (termed 'non-expressors') exhibit two times higher TAC C 0 /D than CYP3A5 *1/*1 and *1/*3 genotypes (collectively termed 'expressors') [11] . ABCB1 1236C>T (rs1128503), 2677G>T/A (rs2032582) and 3435C>T (rs1045642) SNPs have also been widely studied for their effects on TAC PK; however, most studies report no significant effect on TAC C 0 /D [11] [12] [13] 16, 18, 20] . Other relevant SNPs, that is CYP3A4*22 (rs35599367), NR1I2 -25385C>T (rs3814055) and POR*28 (rs1057868), have been less frequently studied, with contradictory findings [14, 17, 18, 20, [22] [23] [24] ; thus, their contributions to TAC PK variability are currently unclear.
We hypothesised that CYP3A5, CYP3A4, ABCB1, POR and NR1I2 genotypes significantly affect TAC C 0 /D. Therefore, we aimed to assess their effect on TAC C 0 /D in the first 3 months post-kidney transplantation. This included investigating the five most common Caucasian ABCB1 SNPs (61A>G (rs9282564), 1199G>A (rs2229109), 1236C>T, 2677G>T and 3435C>T) and their haplotypes together for the first time in kidney transplant recipients. ) as the only calcineurin inhibitor for immunosuppressive therapy (together with mycophenolic acid and prednisolone), were recruited for this study. Those with combined organ transplant or severe liver dysfunction were excluded. One hundred and sixty-five kidney transplant recipients were included. Informed consent was obtained from all participants. According to clinical practice guidelines, TAC was given twice daily and TAC daily dose (D) was adjusted to achieve whole blood target C 0 (8-15 ng/ml) using therapeutic drug monitoring.
Materials and Methods
Participant demographic and clinical data collection. Patient demographics and clinical data were obtained from clinical case notes, including pre-transplant measures of alanine aminotransferase, aspartate aminotransferase and haematocrit. Tacrolimus C 0 for therapeutic drug monitoring was quantified by LC-MS/MS [25] . Intraand inter-assay imprecision and inaccuracy were <12% over the concentration range of 2.4-48.2 ng/ml. TAC D and haematocrit were collected at 1 and 3 months post-transplant. Ltd, Adelaide, SA, Australia) and assay conditions were described previously [26] . Probe-based allelic discrimination assays were developed for ABCB1 (61A>G, 1199G>A, 1236C>T, 2677G>T and 3435C>T), NR1I2 (8055C>T, -25385C>T and 63396C>T) and POR*28 genotyping. The A allele of 2677 G>T/A was not assessed due to its low frequency (~2%) in Caucasians [27] . All primers and probes are described in Table S1 . Three different multiplex assays, ABCB1 61A>G and 3435C>T, ABCB1 1199G>A and 2677G>T, and NR1I2 8055C>T and -25385C>T, were established because their annealing temperatures were compatible ( , Sydney, NSW, Australia), 20 or 40 ng of DNA for single or multiplex assays, respectively, and nuclease-free water (Thermo Fisher Scientific Australia Pty Ltd, Adelaide, SA, Australia) to a 20 ll total reaction volume. Thermocycling conditions and fluorescence detection performed with a CFX96 real-time PCR system (BioRad) were described previously [26] , with annealing temperatures as described in Table 1 . Each assay run of samples included two no-template controls (nuclease-free water) and positive controls of each genotype previously confirmed by Sanger sequencing [26] .
Statistical analysis. Statistical analyses were conducted in R version 3.3.1 [28] unless stated otherwise. Genotype Hardy-Weinberg equilibrium (HWE) was tested by chi-squared test or Fisher's exact test (package::function, genetics [29] ::HWE.chisq and HWE.exact). Pairwise D' and r 2 were calculated to estimate linkage disequilibrium (LD) between loci within a gene (genetics [29] ::LD). ABCB1 haplotypes were inferred using PHASE 2.1 [30, 31] as previously described [32] ; individuals were excluded from further haplotype analysis if their haplotype pairs had low confidence predictions (predicted probability <0.8) due to missing genotype data or rare genotype combinations. Common haplotypes were defined based on a frequency of greater than 0.05. If there were fewer than five homozygotes for an allele or a haplotype, then they were combined with heterozygotes for statistical analysis as follows: CYP3A5*3 grouped as *3/*3 or *1/*1 + *1/*3; ABCB1 61A>G grouped as A/A or A/G + G/G (G allele carriers); NR1I2 8055C>T grouped as C/C or C/T + T/T (T allele carriers); and ABCB1 61-1199-1236-2677-3435 AGCGT and GGTTT haplotypes grouped as 0 copies or 1 + 2 copies (i.e. AGCGT carrier and GGTTT carrier, respectively). Normality of continuous variables (age, haematocrit and TAC C 0 /D) was checked using histograms and quantile-quantile plots (graphics [28] ::hist, stats [28] ::qqnorm and qqline). Log transformation (base 10) of TAC C 0 /D was required to normalize distribution prior to further analysis. All data are expressed as median and interquartile range or range.
Linear mixed effects (LME) analysis (lme4 [33] ::lmer) was used to identify potential genetic predictors of log-transformed TAC C 0 /D. Haematocrit, age and sex have been reported to significantly impact TAC C 0 [34, 35] ; therefore, genotypes/haplotypes were treated as fixed effects adjusted by age, sex and haematocrit whilst patient and time (1 or 3 months) were treated as random effects on intercept. Diagnostic plot (stats [28] ::resid) was applied to check the normality and homoscedasticity of model residuals. Using a forward selection procedure, all SNPs and haplotypes were tested individually controlling for age, sex, haematocrit and random effects. In each selection run, the genetic factor with the lowest p-value which also met the Bonferroni- adjusted threshold (a = 0.05/N) was retained, until no further genetic factors met this criterion. To aid with interpretation of LME findings, the total and relative contributions (model and partial R 2 , respectively (relaimpo [36] ::calc.relimp)) of significant genetic and relevant nongenetic factors to log-transformed TAC C 0 /D variability were determined by multiple linear regression (stats [28] ::lm) of 1 and 3 months post-transplant data separately. Figures were drawn by GraphPad Prism v7 (GraphPad Software, San Diego, CA, USA).
Results
All 165 kidney transplant recipients had at least one TAC C 0 /D measurement at 1 or 3 months post-transplant. Table 1 summarizes recipients' demographic, clinical and TAC C 0 /D data.
Genotype call rates for most SNPs were >98% except for NR1I2 -25385C>T (<80%), thus -25385C>T data were excluded from further analysis. Consequently, 134 patients had data for all SNPs, whilst for 28 patients there were 1-5 missing SNPs and for three patients 6-9 missing SNPs because of limited amount of DNA. Recipient genotype, allele and haplotype frequencies are shown in table 2. Genotype frequencies did not deviate from HWE (p > 0.1) except for CYP3A5*3 (point-wise p = 0.02), with an excess of CYP3A5*1/*1 (table 2). To rule out errors in genotyping, all CYP3A5*1/*1 genotypes were confirmed by Sanger sequencing [26] . Further, this deviation was not a result of mixed-ethnicity in the recipients, as recipient CYP3A5*3 genotype frequencies were similar when considering only Caucasians (2%, 13% and 85% for CYP3A5*1/*1, CYP3A5*1/*3 and CYP3A5*3/*3, respectively).
NR1I2 8055C>T and 63396C>T were not in significant LD (p > 0.7). ABCB1 1236C>T, 2677G>T and 3435C>T variant alleles were all in strong LD with each other (D' = 0.7-0.9, r 2 > 0.4, p < 2 9 10
À16
), and 61A>G and 1199G>A variant alleles were in strong LD with 1236C>T, 2677G>T and 3435C>T variant alleles (D' = 0.9-1.0, r 2 > 0.07, p < 0.005).
However, there was no LD between ABCB1 61A>G and 1199G>A alleles (D' = 1, r 2 = 0.004, p > 0.2). Four common ABCB1 haplotypes were predicted as follows: AGCGC (wildtype for all SNPs), AGCGT, AGTTT and GGTTT. Consequently, a multiple testing-adjusted p-value threshold for initial LME inclusion was determined at 0.004 (a = 0.05/14 tests, 10 SNPs and four haplotypes). Differences in TAC C 0 /D between genotype/haplotype groups at 1 and 3 months post-transplant are summarized in Table S2 . Residual normality and homoscedasticity confirmed by diagnostic plot. Forward selection LME analysis identified CYP3A5*3 and ABCB1 61A>G genotype as the only significant genetic predictors of log-transformed TAC C 0 /D, which was lower in CYP3A5 expressors ( ), CYP3A5*3 explained 25.1% and 30.5%, ABCB1 61A>G 3.0% and 4.3%, and non-genetic variables (combined) 3.9% and 3.5%, of log-transformed TAC C 0 /D variability in these 1 and 3 months post-transplant multiple regression models, respectively.
Discussion
Although the effect of ABCB1 genetic variability on TAC PK has been extensively studied [11] [12] [13] 15, 16, 18, 20, [37] [38] [39] , to our knowledge, this is the first TAC pharmacogenetic study in solid organ transplantation patients to identify a significant impact of ABCB1 61A>G on TAC C 0 /D in the first 3 months post-transplant. A LME model was used to analyse genetic determinants of log-transformed TAC C 0 /D, which allowed for assessment of repeated measurements, accounted for confounding non-genetic effects and adjusted for the expected major effect of CYP3A5*3 genotype in identifying additional genetic factors, such as ABCB1 61A>G. However, since this study was conducted predominantly in Caucasians, the significance of 61A>G is unknown in other ethnicities.
ABCB1 61A>G is a non-synonymous SNP (Asn21>Asp) that does not lead to a significant functional change based on studies of P-gp-mediated transport of fluorescent substrates [40] . However, the mechanism underlying the association observed in this study is not entirely clear because the functional consequences of ABCB1 polymorphisms appear to be substrate-dependent [41] . Whilst Jordan de Luna et al. [37] and S anchez-L azaro et al. [38] found no significant effect of 61A>G on TAC blood concentrations, both studies were in heart transplant recipients and had very small sample sizes (15 and 24 patients receiving TAC therapy, respectively). Very recently, Oetting et al. [20] validated 44 reported SNPs associated with TAC C 0 /D in a cohort of 1560 European-American kidney transplant recipients and reported no significant effect of 61A>G on TAC C 0 /D (p = 0.97). Considering the major effect of CYP3A5*3 on TAC C 0 /D, it is possible that Oetting et al. [20] may have underestimated the effect of 61A>G, as the CYP3A5*3 genotype effect was not adjusted for in their LME modelling. In contrast, our results showed 61A>G significantly decreased TAC C 0 /D in kidney transplant recipients, but only after adjusting for CYP3A5*3 genotype and the effect was small relative to CYP3A5*3 genotype, and will need replication.
Of the other ABCB1 SNPs included in this study, 1199G>A decreases P-gp efflux and increases TAC intracellular accumulation in vitro [42, 43] ; however, similar to our observations, it was not associated with TAC C 0 /D previously [12, 20] . ABCB1 3435C>T reduces ABCB1 mRNA stability and P-gp expression [44, 45] , and is in strong LD with 1236C>T and 2677G>T [18, 39] . These three ABCB1 SNPs, along with their haplotypes, are frequently studied in TAC PK; however, their impact remains uncertain. Although some associations have been reported [15, 39] , most studies, including ours, have found no effect of these ABCB1 genotypes/haplotypes on TAC C 0 /D [11] [12] [13] 16, 18, 20] . Further, two meta-analyses of the impact of 3435C>T SNP [46, 47] (n = 1386 and 1327, respectively) were conducted, and both suggested an inconsistent effect on TAC C 0 /D that was dependent on the time posttransplantation.
This study confirmed that CYP3A5*3 non-expressors have higher TAC C 0 /D than CYP3A5*3 expressors. CYP3A5*3 genotype frequencies deviated from HWE (P = 0.02) in our study, which has been found in other studies [3, 48] . This may be due to individuals not being from a truly random population (kidney transplant recipients), or simply by chance given 10 HWE tests were carried out in our study. Importantly, CYP3A5*1/*1 genotypes were confirmed by sequencing, and this assay has been used without deviation from HWE in other populations [25] , indicating systematic genotyping errors are unlikely to explain the deviation.
We did not observe any effect of CYP3A4*22 or POR*28 on TAC C 0 /D. Theoretically, the CYP3A4*22 and POR*28 SNPs can potentially affect TAC PK. In vitro studies have found that CYP3A4*22 decreases CYP3A4 mRNA expression and activity by 40-60% [49] , whilst the POR*28/*28 genotype increases CYP3A activity by 60% [8] . Oetting et al. [20] reported CYP3A4*22 was significantly associated with increased TAC trough blood concentrations (p = 4.8 9 10 À19 ) in 1560 European-American kidney transplant recipients. Two independent kidney transplant studies (n = 241 and 49) [16, 23] also reported that CYP3A4*22 carriers had higher TAC C 0 /D than non-carriers (30% and 100%, respectively); whereas Santoro et al. [14] (n = 140) and Pulk et al. [19] (n = 1407) reported no effect of CYP3A4*22 on TAC C 0 /D. In a study of 298 kidney transplant recipients, De Jonge et al. [22] identified that POR*28 carriers (n = 23) had statistically significant lower TAC C 0 /D, but only in the CYP3A5*3 expressor subgroup. This effect was subsequently confirmed by Elens et al. [50] (n = 184) and Pulk et al. [19] (n = 1429), however, of these significant results (point-wise pvalues = 0.03 and 0.04, respectively) only Elens et al. [50] adjusted for multiple comparisons. In contrast, Jannot et al. [24] (n = 229) and Oetting et al. [20] (n = 1560) found no effect of POR*28 on TAC C 0 /D in kidney transplant recipients. In other studies, the CYP3A4*22 and POR*28 SNPs were analysed in combination with CYP3A5*3 to generate fast/intermediate/slow metabolizer groups [51, 52] or to calculate CYP3A4/5 scores [23, 39] ; thus, the independent effect of CYP3A4*22 or POR*28 on TAC PK was not reported. More research and meta-analyses are therefore needed to address these discrepancies regarding the roles CYP3A4*22 and POR*28 play in TAC PK variability. The NR1I2 8055T allele is associated with two times increased intestinal CYP3A inducibility [53] , and the 63396 C/C genotype is associated with three times lower basal and rifampin-inducible CYP3A4 activity [54] . However, there were no effects of 8055C>T or 63396C>T genotypes on TAC C 0 /D in this study. Whilst we are the first to investigate 63396C>T in this setting, two previous studies have similarly reported no effect of 8055C>T on TAC 0 /D [17, 20] . The NR1I2 -25385T allele is also associated with two times increased intestinal CYP3A inducibility [53] . In three independent kidney transplant recipient cohorts (n = 142, 159 and 1923, respectively) [13, 18, 20] , no difference in TAC C 0 /D was reported between -25385C>T genotype groups. In contrast, Kurzawski et al. [55] recently reported that -25385C/C genotype carriers had significantly lower TAC C 0 /D (p = 0.005) in 240 Caucasian kidney transplant recipients. Unfortunately, we were unable to investigate the effect of -25385C>T on TAC C 0 /D due to poor assay performance with our samples, and insufficient DNA for re-analysis. Hence, it remains unclear what effect -25385C>T has on TAC PK.
As with any study, there were some notable limitations that need to be considered. For example, our study had a relatively limited sample size, and some homozygous genotypes (i.e. ABCB1 61G/G, NR1I2 8055 T/T) needed to be combined with heterozygote genotypes for statistical analysis or were not observed (CYP3A4*22/*22, ABCB1 1199A/A). Therefore, we cannot rule out effects of these homozygous variant genotypes. Additionally, we had no record of recipients' co-medications and so could not assess potential drug-drug interactions with TAC. Finally, our current model explains less than 40% of TAC C 0 /D variability, which although similar to the 18-42% variability found by other investigators [15, 17, 18, 20] , indicates novel genetic and non-genetic factors (i.e. co-administration of CYP3A inducers and/or inhibitors) need to be examined in future studies.
In conclusion, this study investigated potential genetic causes of inter-individual variability in TAC C 0 /D by studying SNPs in the genes encoding TAC metabolizing enzymes, transporter, co-factor and regulator. Our approach has enabled us to confirm the significant effect of CYP3A5*3 and to detect the novel although minor effect of ABCB1 61A>G on TAC C 0 /D for the first time.
